CSC Intelligent Financial Information Pharmaceutical Technology (300725) said on Interactive easyBlackrouletteIn 2023, the company's innovative Chemical Technology Center (TIC) established a synthetic biology team in the original biocatalysis department, which is committed to the deeper and wider application of biotechnology and fermentation technology to develop and manufacture new drug molecules and their intermediates, and to continuously develop small molecular compounds.BlackrouletteWith the application of enzyme catalysis technology, a number of high-value products such as chiral amino acids, chiral amines and chiral benzylamines are formed, which promote the reserve of novel molecular block products of the company. in addition, it also provides the whole process services of enzyme evolution, fermentation enzyme production, chemical screening and process development, workshop production and IP support for CDMO business.
Based on the positioning of the synthetic biology technology support platform, its economic benefits are mainly reflected in the development of main businesses such as molecular blocks and CDMO in services, improving the penetration of new technologies in development and production projects, thereby reducing costs and enhancing market competitiveness, etc., and services have not been opened to the public in 2023, so there is no independent out-of-warehouse sales in that year's sales revenue. In the follow-up, the synthetic biology team will aim at independent technology output and product sales, continue to expand and improve the biocatalysis platform, and promote the green and sustainable development of chemistry and chemical industry.
In addition, in 2023, the company continued to expand global customer cooperation, with foreign customers accounting for 68% of the revenueBlackroulette.48%. Of which, revenue from North American customers 9Blackroulette8 billion yuan, accounting for 56.82% of the company's operating income; 137 million yuan from European customers, accounting for 7.98% of the company's operating income; and 64 million yuan from Japan, South Korea and other regions, accounting for 3.68% of the company's operating income.
Pharma Technology is a global one-stop CRDMO supplier in the field of pharmaceutical R & D and manufacturing. Provide global partners with a full range of drug screening, development and production solutions through their own R & D and production platforms. The company's products and services are mainly used in pharmaceutical enterprises' new drug R & D projects, and the company's business is closely related to the development of global new drug R & D and R & D and production outsourcing industry.
In 2023, the company achieved a total operating income of 1.725 billion yuan, an increase of 8.18% over the same period last year, with a net profit of 197 million yuan and basic earnings per share of 0.99 yuan. The company's annual profit distribution plan for 2023 is to distribute 3.1 yuan (including tax) to all shareholders for every 10 shares.
(article source: China Securities News, China Securities Network)
